Revised: July 16, 2026

Ketosis simply means your blood ketones (often β-hydroxybutyrate, βHB) are elevated because carbohydrate availability is low (fasting, very-low-carb diets) or because you ingested ketones.
That metabolic state can have specific, real physiologic effects—but “being in ketosis” is not the same thing as “reducing atherosclerosis risk,” “reversing heart disease,” or “living longer.” Whether ketosis helps or harms depends heavily on what foods create it and what it does to apoB/LDL, blood pressure, inflammation, body weight, and diet quality.
The evidence is mixed and context-dependent. The best-known ketone ester work shows that exogenous ketosis can change fuel use (more fat oxidation, less glycolysis) and has sometimes been associated with endurance performance effects in controlled settings, but results vary by dose, sport, intensity, co-ingested carbs, and GI tolerance (1–3).
A major scientific point: ketone esters can raise βHB quickly and predictably, which is useful for studying ketosis without changing the whole diet. That’s a research advantage, not a guarantee of performance gains in the real world (4).
Conclusions: some athletes may see benefits in specific endurance contexts, but exogenous ketones are not a universally proven ergogenic aid; and GI side effects and practical cost/taste issues are real constraints (5).
Short-term improvements in glucose control and weight are real for many people, especially in type 2 diabetes—often because carbohydrate restriction reduces glycemic load and can facilitate weight loss and medication reduction (6).
But two key scientific caveats:
Keto can be a useful therapeutic tool for glycemia and weight in some people, but it is not automatically the best choice for heart disease reversal or longevity, and lipid responses can be a deal-breaker for some.
There are two landmark clinical lines of evidence often cited because they used objective coronary imaging and tracked clinical outcomes:
1) Ornish/Lifestyle Heart Trial (randomized):
Participants assigned to intensive lifestyle change including a very-low-fat, whole-foods vegetarian diet showed regression of coronary atherosclerosis vs. controls in the first year, and sustained benefits were reported in longer follow-up (9).
Five-year follow-up showed continued regression in the intensive group and more cardiac events in controls (10).
2) Esselstyn cohort (longitudinal clinical series):
A very-low-fat plant-based diet in patients with established CAD was associated with arrest and, in some cases, reversal of disease over years, with outcomes strongly linked to adherence (11).
Are these perfect studies? No—sample sizes were modest and lifestyle bundles include more than diet. But the direction and plausibility are powerful: when you dramatically reduce atherogenic lipoproteins and emphasize high-fiber, minimally processed plant foods, coronary disease progression can slow, stop, and sometimes regress.
If your goal is reversing atherosclerosis, the most direct clinical evidence base favors very-low-fat, whole-food plant-forward patterns paired with comprehensive risk-factor management (9–11). So clearly plant based diets win clearly in my opinion.
Yes—there are randomized trials showing meaningful metabolic benefits:
Mechanistically, one consistent theme is that high-fiber, low–energy-density plant foods can promote spontaneous calorie reduction, and lowering intramyocellular/liver fat may improve insulin resistance—often without needing ketosis.
Conclusions: you don’t need ketosis to improve insulin sensitivity; well-designed plant-based diets can do it, and the approach often aligns better with heart-protective lipid targets (12–14).
Because atherosclerosis risk is driven heavily by apoB-containing particles (LDL, VLDL remnants) and cumulative exposure over time.
In nutritional ketosis interventions, it’s common to see lower triglycerides and sometimes higher HDL, but some studies report higher LDL-C (and variable LDL particle effects) (7,8).
If LDL/apoB rises substantially—especially if the diet is high in saturated fat—this can conflict with the core lipid-lowering strategy used to prevent and treat atherosclerotic disease.
Metabolic “wins” don’t automatically cancel out a large rise in LDL/apoB.
In human population studies, dietary patterns associated with lower mortality and lower ischemic heart disease risk generally skew plant-forward rather than very-low-carb/high-fat.
Two large prospective datasets often discussed in this context:
These aren’t “whole-food plant-based” trials, and observational data can’t prove causation. But they’re consistent with a broad scientific pattern: diets centered on minimally processed plant foods are compatible with long-term cardiometabolic health and lower mortality.
The best longevity-linked dietary patterns in large cohorts look much closer to plant-forward than to strict keto.
If your primary goal is heart disease reversal / atherosclerosis regression:
A very-low-fat, whole-food, plant-based pattern has some of the strongest direct clinical signals (including angiographic evidence) and aligns with LDL/apoB lowering (9–11).
If your primary goal is short-term glucose control or appetite/weight help:
Low-carb/keto can work for some—especially in type 2 diabetes—but the advantage may lessen over time and lipid responses should be monitored closely (6–8).
If your goal is longevity / chronic disease risk reduction at scale:
The strongest population evidence tilts toward plant-forward patterns (with attention to nutrient adequacy like B12) (15,16).
Transparency Note: This blog post was created with assistance from AI tools. The final content has been carefully reviewed and edited by the author, who is responsible for its accuracy. The information provided is for educational purposes only and does not constitute medical advice.
Educational family-history heart risk calculator with H-score insights, visual family tree input and shareable PDF reports.